Functional differences between two classes of oncogenic mutation in the PIK3CA gene.

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• PIK3CA gene mutations are common in various cancers.
• These mutations occur in the helical and kinase domains of the p110alpha isoform of class-IA PI 3-kinase.
• Understanding mutant biochemical properties is crucial for targeted cancer therapies.

Purpose of the Study:

• To investigate the biochemical properties of common PIK3CA helical domain (E545K) and kinase domain (H1047R) mutants.
• To compare the activation mechanisms of these mutants with wild-type (WT) p110alpha.
• To assess the differential responses of mutants to growth factor and H-Ras signaling.

Main Methods:

• Biochemical characterization of WT p110alpha, E545K, and H1047R mutants.
• Enzyme kinetics assays measuring V(max) and inhibition by PI 3-kinase inhibitors (Wortmannin, LY294002, PI-103, PIK-75).
• Assessment of mutant activation by platelet-derived growth factor (PDGF) and H-Ras.

Main Results:

• Both E545K and H1047R mutants showed increased V(max) and similar inhibition by PI 3-kinase inhibitors as WT p110alpha.
• PDGF increased V(max) for WT p110alpha but not for E545K, and decreased it for H1047R.
• E545K mutant was activated by H-Ras, whereas H1047R mutant was not.

Conclusions:

• PIK3CA helical domain mutants (E545K) appear constitutively active, mimicking growth factor signaling.
• PIK3CA kinase domain mutants (H1047R) mimic activation states similar to H-Ras signaling.
• These distinct activation mechanisms offer insights into differential therapeutic strategies for PIK3CA-driven cancers.